Back to top
more

Lannett Co Inc (LCI)

(Delayed Data from NYSE)

$8.54 USD

8.54
1,487,457

+0.70 (8.93%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.54 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[LCI]

Reports for Purchase

Showing records 381 - 400 ( 421 total )

Industry: Medical - Drugs

Record: 381

10/10/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 382

10/10/2013

Company Report

Pages: 5

Levo Pricing Upside Drives Higher EPS Forecasts; PT to $23.50

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 383

09/11/2013

Company Report

Pages: 6

FY4Q13 Recap - Trends Remain Positive - Upping #''s and PT

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 384

08/21/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 385

08/20/2013

Company Report

Pages: 5

JSP Extension Reduces Risk, PT to $15

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 386

07/23/2013

Company Report

Pages: 2

We are transferring coverage as a result of reorganization of our coverage universe

Provider: STONEGATE CAPITAL MARKETS

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 387

05/15/2013

Company Report

Pages: 12

Beating expectations while Company prepares for C-Topical expansion

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 388

05/09/2013

Daily Note

Pages: 4

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 389

05/09/2013

Company Report

Pages: 6

FY3Q13 Recap - Business is Good

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 390

05/02/2013

Daily Note

Pages: 4

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 391

05/01/2013

Company Report

Pages: 5

FY3Q13 Preannounced Upside - Levo Likely the Driver

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 392

03/12/2013

Company Report

Pages: 12

Q412 Results Miss Expectations But New Business Points in the Right Direction

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 393

02/15/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 394

02/14/2013

Company Report

Pages: 8

Updated model

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 395

02/12/2013

Company Report

Pages: 12

Company Revenue from Cardiovascular medicines continue to make our heart race Q2FY13 results beat our modeled numbers

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 396

02/01/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 397

02/01/2013

Company Report

Pages: 5

Quarterly Trends Ahead of Forecast, Upping PT

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 398

11/16/2012

Company Report

Pages: 12

Q1FY13 results beat our modeled numbers

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 399

11/09/2012

Company Report

Pages: 6

1Q13 Update - Reiterate Buy on Revenue Strength

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 400

10/08/2012

Company Report

Pages: 2

We are transferring coverage of LCI to Marco Rodriguez as the previous analyst is no longer with the firm.

Provider: STONEGATE CAPITAL MARKETS

Price: 10.00

Research Provided by a Third Party
// eof